Tirofiban

Key facts

Drug.verifiedrevid

470610777

Drug.image

Tirofiban.svg

Drug.image_class

skin-invert-image

Drug.width

290

Drug.image2

Tirofiban ball-and-stick.png

Drug.image_class2

bg-transparent

Drug.tradename

Aggrastat

Drug.MedlinePlus

a601210

Drug.DailyMedID

Tirofiban

Drug.pregnancy_AU

B1

Drug.routes_of_administration

intravenous

Drug.ATC_prefix

B01

Drug.ATC_suffix

AC17

Drug.legal_US

Rx-only

Drug.legal_status

Rx-only

Drug.protein_bound

65%

Drug.elimination_half life

2 hours

Drug.IUPAC_name

(2S)-2-[(butylsulfonyl)amino]-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid

via Wikipedia infobox

Chemical data

Formula

C22H36N2O5S

Molecular weight

440.6 g/mol

IUPAC name

(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid

SMILES

CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O

InChIKey

COKMIXFXJJXBQG-NRFANRHFSA-N

XLogP

1.4

Polar surface area

113 Ų

H-bond donors

3

H-bond acceptors

7

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Small molecule

First approval

1998

Admin. routes

parenteral

Indications

myocardial infarction, acute coronary syndrome, Recurrent thrombophlebitis, venous thromboembolism

via ChEMBL · EBI

• Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.The New England journal of medicine · 2025
• Tirofiban-induced thrombocytopenia.Annals of medicine · 2023
• Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.JAMA neurology · 2024
• Tirofiban in emergency conditions.The American journal of emergency medicine · 2022
• Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies.Drugs · 2025

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

440.234

Has use

medication

via Wikidata · CC0